ClinicalTrials.gg
RecruitingNCT07205159Updated Nov 20, 2025

A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.

A Phase 1 interventional study of FB102 and Placebo in Alopecia Areata, sponsored by Forte Biosciences, Inc.. Recruiting at 6 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Forte Biosciences, Inc. (part of argenx) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Alopecia Areata with a site in Australia — 3 open to participants now, 4 under way, 2 of them phase 3. Alopecia Areata · Australia.

Planned enrollment
13th of 15
32 · median 94
Started
2025
the only one that year
Phase 1
3 of 15
1 open now
Registered
14th of 15
by date
Lead sponsor
1 of 15
Forte Biosciences, Inc.

Among the 15 studies in Alopecia Areata with a site in Australia, this one is the 13th largest by planned enrollment, is the only one that started in 2025, is one of 3 in phase 1, and was the 14th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

3 of the 15 studies in Alopecia Areata with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Alopecia Areata with a site in Australia, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of FB102 in patients with severe to very severe alopecia areata (AA).

Read the detailed description

Up to approximately 32 participants who meet all the Screening eligibility criteria will be randomized in a 3:1 ratio to receive FB102, or placebo dosing to match.

03

Conditions studied

  • Alopecia Areata

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males aged 18-60 years and females aged 18-75 years at Screening.
  • Clinical diagnosis of severe to very severe AA with ≥50% scalp hair loss (including AT or AU) confirmed by SALT score and central photo review; no other cause of hair loss.

    • AT = complete scalp hair loss; AU = complete scalp, facial, and body hair loss. Note: There are additional inclusion criteria. The study center will determine if participant meets all of the criteria

Exclusion criteria

Exclusion Criteria:

  • Other types of alopecia (e.g., diffuse AA, traction, scarring alopecia, telogen effluvium, trichotillomania, chemotherapy-induced hair loss, androgenetic alopecia).
  • Other scalp diseases impacting AA assessment (e.g., psoriasis, dermatitis, tinea capitis).
  • Active systemic diseases causing hair loss (e.g., lupus, thyroiditis, systemic sclerosis, lichen planus, syphilis).

Note: There are additional exclusion criteria. The study center will determine if participant meets all of the criteria

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (estimated)

Study arms

  • Active comparator
    FB102

    Participants will receive FB102.

    Drug: FB102

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: Placebo

Interventions

  • DrugFB102

    Route of administration- Intravenous (IV)

  • DrugPlacebo

    Route of administration- Intravenous (IV)

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: Upto 36 Weeks post first dose administration

  2. Change from Baseline of Severity of Alopecia Tool (SALT) score at Week 16.

    The Severity of Alopecia Tool (SALT) score ranges from 0 (no scalp hair loss) to 100 (complete scalp hair loss), with higher scores indicating greater severity. Change from baseline in SALT score at Week 16 will assess treatment effect. The AA-IGA categorizes SALT scores as follows: 0 = None (0%), 1 = Limited (1-20%), 2 = Moderate (21-49%), 3 = Severe (50-94%), 4 = Very Severe (95-100%).

    Time frame: From Screening through Week 16.

07

Study locations

1 of 6 sites recruiting
  • St Leonards
    Saint Leonards, New South Wales (nsw) 2065, Australia
    Not yet recruiting
  • Coorparoo
    Coorparoo, Queensland 4151, Australia
    Recruiting
  • South Yarra
    South Yarra, Victoria 3141, Australia
    Not yet recruiting
  • Auckland
    Auckland, Auckland 0632, New Zealand
    Not yet recruiting
  • Christchurch
    Christchurch, Canterbury 8013, New Zealand
    Not yet recruiting
  • Palmerston North
    Palmerston North, Palmerston North Central 4414, New Zealand
    Not yet recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Mar 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2025
First posted
Oct 3, 2025
StartActual
Oct 23, 2025
Primary completionEst.
Mar 10, 2027
CompletionEst.
Mar 10, 2027
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07205159
Responsible party
Sponsor
First posted
Oct 3, 2025
Start date
Oct 23, 2025
Primary completion
Mar 10, 2027 (estimated)
Completion
Mar 10, 2027 (estimated)
Last update
Nov 20, 2025

Study contacts

Support Officer
Contact
recruitment@clinibase.com
+61 3 7050 1941

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FB102

Start the discussion